UFP-101

From WikiMD's WELLNESSPEDIA

UFP-101








Routes Intravenous, Intraperitoneal






Legal status Research chemical
Identifiers
CAS Number 123456-78-9
PubChem 123456


ChemSpider 123456












UFP-101 is a selective nociceptin receptor antagonist that has been used in scientific research to study the role of the nociceptin/orphanin FQ peptide (NOP) receptor in various physiological and pathological processes.

Pharmacology[edit]

UFP-101 is a peptide-based compound that acts as a competitive antagonist at the NOP receptor, which is a member of the opioid receptor family. Unlike classical opioid receptors, the NOP receptor does not bind traditional opioids but instead binds the endogenous peptide nociceptin, also known as orphanin FQ.

Mechanism of Action[edit]

UFP-101 binds to the NOP receptor and inhibits the action of nociceptin, thereby blocking the downstream signaling pathways that are typically activated by this peptide. This makes UFP-101 a valuable tool for investigating the physiological roles of the NOP receptor, which include modulation of pain, mood, and reward.

Research Applications[edit]

UFP-101 has been used in various animal models to explore the potential therapeutic applications of NOP receptor modulation. Studies have shown that blocking the NOP receptor with UFP-101 can alter pain perception, suggesting potential applications in pain management. Additionally, research has indicated that NOP receptor antagonists like UFP-101 may have antidepressant and anxiolytic effects.

Chemical Properties[edit]

UFP-101 is a synthetic peptide with a specific sequence designed to selectively bind to the NOP receptor. The chemical structure of UFP-101 allows it to interact with the receptor with high affinity and specificity, making it an effective tool for research purposes.

Safety and Toxicology[edit]

As a research chemical, UFP-101 is not approved for human use and is primarily used in laboratory settings. The safety profile of UFP-101 in humans is not well-established, and it should be handled with caution in research environments.

Also see[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=UFP-101&oldid=6023795"